Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jan 28;17(3):470.
doi: 10.3390/nu17030470.

From Evidence to Practice: A Narrative Framework for Integrating the Mediterranean Diet into Inflammatory Bowel Disease Management

Affiliations
Review

From Evidence to Practice: A Narrative Framework for Integrating the Mediterranean Diet into Inflammatory Bowel Disease Management

Riya Gautam Naik et al. Nutrients. .

Abstract

Emerging evidence underscores the pivotal role of diet in preventing and managing inflammatory bowel disease (IBD). As our comprehension of the microbiome's role in IBD expands, dietary modifications are increasingly recognized as potential adjuncts or primary therapeutic strategies. Key components of the Mediterranean diet (MD)-including microbiota-accessible carbohydrates, omega-3 fatty acids, polyphenols, and antioxidants-have demonstrated promise in enhancing gut microbiota diversity and reducing intestinal inflammation, making it a practical approach for managing IBD. Moreover, the MD offers additional benefits considering the rising prevalence of comorbid chronic inflammatory conditions such as diabetes, cardiovascular disease, and obesity in IBD patients. The purpose of this narrative review was to provide an overview of the feasibility and clinical outcomes of the MD and offer evidence-based guidance for researchers and practitioners on how to adapt the MD to patients with IBD. According to several cross-sectional and interventional studies, the MD is feasible for patients with IBD and confers several benefits, such as reduced inflammation, improved disease activity, and enhanced quality of life, with a strong adherence rate and minimal adverse effects. To facilitate knowledge translation, we provide a practical framework for integrating the MD as a nutritional therapy for IBD, including specific recommendations and messaging that researchers, practitioners, and patients can use. By synthesizing current evidence and offering actionable insights, the aim is to facilitate the integration of the MD into IBD management, with the potential to improve patient outcomes.

Keywords: Crohn’s disease; Mediterranean diet; nutrition therapy; ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Visual comparison of dietary choices during remission versus active disease. This comparison highlights the practical implications tailored to different phases of IBD. During remission, patients can focus on nutrient-dense, whole foods such as nuts, legumes, fruits, and vegetables, consumed as tolerated. These choices support gut health, reduce inflammation, and promote overall well-being. During active disease, to ease digestion and minimize discomfort, the texture of foods can be modified—such as opting for cooked, peeled, or blended versions of fruits and vegetables and avoiding high-fiber, hard-to-digest items like nuts or raw legumes (Visual created by Leah D. D’Aloisio).

Similar articles

Cited by

References

    1. Benchimol E., Bernstein C.N., Bitton A., Murthy S.K., Nguyen G.C., Lee K., Cooke-Lauder J., Siddiq S., Windsor J.W., Carroll M.W., et al. The Impact of Inflammatory Bowel Disease in Canada 2018: A Scientific Report from the Canadian Gastro-Intestinal Epidemiology Consortium to Crohn’s and Colitis Canada. J. Can. Assoc. Gastroenterol. 2019;2:S1–S5. doi: 10.1093/jcag/gwy052. - DOI - PMC - PubMed
    1. Noor N.M. Combination therapies: The next major frontier in IBD management. Nat. Rev. Gastroenterol. Hepatol. 2023;20:761. doi: 10.1038/s41575-023-00839-3. - DOI - PubMed
    1. Singh S., George J., Boland B.S., Casteele N., Sandborn W.J. Primary non-response to tumor necrosis factor antagonists is associated with inferior response to second-line biologics in patients with Inflammatory bowel diseases: A systematic review and meta-analysis. J. Crohns Colitis. 2018;12:635–643. doi: 10.1093/ecco-jcc/jjy004. - DOI - PMC - PubMed
    1. Ananthakrishnan A.N., Kaplan G.G., Ng S.C. Changing Global Epidemiology of Inflammatory Bowel Diseases: Sustaining Health Care Delivery Into the 21st Century. Clin. Gastroenterol. Hepatol. 2020;18:1252–1260. doi: 10.1016/j.cgh.2020.01.028. - DOI - PubMed
    1. Zhao M., Feng R., Ben-Horin S., Zhuang X., Tian Z., Li X., Ma R., Mao R., Qiu Y., Chen M. Systematic review with meta-analysis: Environmental and dietary differences of inflammatory bowel disease in Eastern and Western populations. Aliment. Pharmacol. Ther. 2022;55:266–276. doi: 10.1111/apt.16703. - DOI - PubMed

MeSH terms

LinkOut - more resources